I. Welcome and Announcements (5 minutes)
   - CCP Executive Officer, Paul Reiter, PhD

II. Guest Presentation (15 min presentation/5 mins Q&A)
   A. Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
      Emily Finlayson, MD

III. ASCO Presentations (15 min presentation/5 mins Q&A each)
   A. Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time (A151527)
      Rachel Freedman, MD, MPH
   B. Identifying Risk Factors for Toxicity in Patients with Hormone-receptor Positive Advanced Breast Cancer Treated with Bevacizumab Plus Letrozole: a CALGB 40503 (Alliance) Correlative Study
      Daneng Li, MD
IV. New Concepts (15 min presentation/5 mins Q&A each)
A. Pooled Survival Analysis of Elderly Patients Enrolled in CALGB Trials for First-line Doublet Therapy in Advanced NSCLC
   Josephine (Joy) L. Feliciano, MD

V. Study Updates (5-10 min presentation/5 mins Q&A each)
A. A171302: Musculoskeletal Events in Elderly Patients Receiving Adjuvant Chemotherapy for Breast Cancer and Proposal for 369901 Data
   Judy Hopkins, MD
B. A151436 - The Impact of Body Size on Toxicities and Outcome with Weight-Based Cytotoxic Chemotherapy Dosing - Data from CALGB 49907
   Vicki Morrison, MD
C. A151503: Estimate of Survival and Validating Using the Online Prognosis Estimation from Eprognosis
   Gretchen Kimmick, MD
D. A151509: Comparison of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) with Other Consolidation Therapies Per Alliance Protocols in Older (≥60 years) AML Patients in First Complete Remission (CR1)
   Andy Artz, MD & Cela Ustun, MD
E. A151511: Data Study: Cardiotoxicity and Malignant Hematologic Complications Among Older Patients Receiving Anthracycline-based Adjuvant Chemotherapy for Breast Cancer on Modern Cooperative Group Trials
   Rachel Freedman, MD, MPH
F. Update on Intergroup Trials for Older Adults with AML
   Heidi Klepin, MD
G. Feasibility of an Electronic Geriatric Assessment (eGA) for Older Adults with Cancer
   Emily Guerard, MD

VI. Notation Items:
A. Study Tracker
B. Publications Since November 2015 Meeting
   Manuscripts:
   • Li, D, Dickler, MN, McCall, LM, Hahn, OM, Hudis, CA, Cohen, HJ, Muss, HB, Ballman, KV, Winer, EP, Tripathy, D, Schneider, B, Cirrincione, C, Barry, W and Hurria, A. "Identifying risk factors for toxicity in patients with hormone-receptor positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (Alliance) correlative study." ASCO 2016 Poster Presentation. http://cancerres.aacrjournals.org/content/76/4_Supplement/P6-09-10.abstract. (Study: A151503, C49907, C369901)

VII. Other Business